Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nan Fung Life Sciences
BioCentury | Mar 21, 2024
Finance
Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail
Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience
BioCentury | Jan 4, 2022
Finance
Aiming for rare disease niche, Europe biotech vets form Sound Bioventures
With €110M first close completed, Swedish VC led by Breum, Kördel, Mukhopadhyay will seek to back programs entering or nearing the clinic
BioCentury | Nov 19, 2021
Finance
Nov. 18 Quick Takes: RA’s Avilar raises $60M seed for protein degradation tech
Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali
BioCentury | Aug 4, 2021
Deals
Aug. 3 Quick Takes: BeiGene picks N.J. for new campus
Plus Zentera, Iterative Scopes, BMS, Novartis, Mestag, Engrail, AbCellera-Tachyon, Outlook
BioCentury | May 5, 2021
Deals
May 4 Quick Takes: Oxford Nanopore raises £195M ahead of planned IPO; plus Pfizer, Oculis, MoonLake, Aceragen, Yarrow-ProQR, BioLineRx and more
BioCentury | Mar 11, 2021
Deals
March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis
Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage
BioCentury | Jan 29, 2021
Finance
Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more
Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5
BioCentury | Sep 23, 2020
Management Tracks
Gilead BD head Bender takes top job at pediatric cancer start-up Day One
Bowers to head commercial as Canaan-incubated biotech builds out team
BioCentury | Aug 29, 2020
Emerging Company Profile
Arctic Vision sets sights on China’s innovation gap in ophthalmology
A veteran of MNCs, Eddy Wu launches biotech to in-license and discover eye therapies
BioCentury | Jul 16, 2020
Emerging Company Profile
Fountain Therapeutics: an AI-based platform to reverse cellular aging
Fountain’s AI-driven platform measures cellular age as the basis for anti-aging drug screens
Items per page:
1 - 10 of 35